Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B

Ferraz, M.L.G.; Strauss, Edna; Perez, Renata M.; Schiavon, Leonardo Lucca; Ono, Suzane Kioko; Ferreira, Adalgisa P.; Nabuco, Leticia Cancella; Carvalho-Filho, Roberto José de; Tovo, Cristiane Valle; Souto, Francisco José Dutra; Abrão, Paulo; Reuter, Tânia; Dantas, Thor Oliveira; Vigani, Aline Gonzalez; Porta, Gilda; Ferreira, Marcelo Simão; Paraná, Raymundo; Cimerman, Sérgio; Bittencourt, Paulo Lisboa

doi:10.1016/j.bjid.2020.07.012

Cited by 12 publications

(28 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This number was lower than the ones found in healthy adults, which was more than 90% and greater than the number between patients with Down syndrome. 9,17,18 But regarding HCVinfected individuals, the data in the literature was variable. Some studies have shown similar numbers to our result and other had a better vaccinal response.…”

Section: Discussionmentioning

confidence: 99%

Low response rates to hepatitis B vaccine in patients with chronic hepatitis C

Ivantes¹,

Passos

Moraes

et al. 2021

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: Hepatitis B is an infectious disease with converging routes of transmission with hepatitis C, making vaccination important in hepatitis C infected people. The objective was to evaluate the vaccine response against hepatitis B virus (HBV) in patients with chronic hepatitis C virus (HCV).Methods: Retrospective observational study was conducted between November 2018 and April 2020. Subjects with anti-HBs levels ≥10 mUI/ml were considered protected against HBV and those with chronic HCV who did not receive at least one dose of the vaccine schedule or with anti-HBc reagent or even with anti-HBs positive prior to the first dose documented in the HBV vaccine record were excluded. The immune response rates to VHB vaccine in patients with HCV was obtained and different variables were analysed.Results: The study group was compound of 370 subjects. The majority (55.7%) were male, with a median age of 55.6±11 years. Regarding present or past smoking, 56.9% of patients reported that were active or past tobacco users. HCV genotype 1 corresponded to 59.7% of the cases, followed by genotype 3 (36.88%). One hundred and fourteen (30.9%) of the patients had liver cirrhosis. The immune response to complete HBV vaccine was 62.3%, whereas the response to a single dose was 57.1% (p=1). Only the age of the patient at first dose (p=0.030), smoking status (p=0.017) and the presence of cirrhosis (p=0.046) influenced the immune response to HBV vaccine.Conclusions: The rate of immune response to standard schedule of HBV vaccination in patients with HCV was low (62.3%).

show abstract

Section: Discussionmentioning

confidence: 99%

Low response rates to hepatitis B vaccine in patients with chronic hepatitis C

Ivantes¹,

Passos

Moraes

et al. 2021

Int J Community Med Public Health

View full text Add to dashboard Cite

show abstract

“…ALEH recommends surveillance for HCC preferably with semiannual ultrasound in patients with cirrhosis and in some other at-risk populations, among whom are individuals infected with HBV. According to its guidelines, AFP could be used as a biomarker in the absence of quality ultrasound [45] . However, it should be noticed that a recent meta-analysis has demonstrated an increase in sensitivity when both methods are used together [48] .…”

Section: Methodology and Frequency Of Surveillancementioning

confidence: 99%

“…ALEH recommends surveillance for HCC in patients with cirrhosis and in some at-risk populations infected with HBV. Nevertheless, its guidelines do not specify when surveillance should begin in patients with HBV who do not have cirrhosis [45] . Considering the early development of HCC in Latin American patients with HBV, it might be argued that the age for surveillance should probably be anticipated in relation to that of individuals of European ancestry and closer to what is recommended for Asian or African individuals [32] .…”

Section: Target Populationmentioning

confidence: 99%

Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology

Anugwom¹,

Allaire²,

Akbar³

et al. 2021

View full text Add to dashboard Cite

Hepatitis B infection (HBV) is one of the most common causes of hepatocellular carcinoma (HCC) worldwide. The age of occurrence, prognosis and incidence vary dramatically depending on the region of the world. This geographic variation is largely dependent on the contrasting incidence of HBV, age of transmission of the virus, the timing of integration into the human genome, and different HBV genotypes, as well as environmental factors. It results in a wide difference in viral interaction with the immune system, genomic modulation and the consequent development of HCC in an individual. In this review, we describe many factors implicated in HCC development, provide insight regarding at-risk populations and explain societal recommendations for HCC surveillance in persons living with HBV in different continents of the world.

show abstract

“…HBV infection has a high impact on public health worldwide 1 due to the potential risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC). 2 , 3 The HBV genome is made up of partially double DNA strand with approximately 3,200 base pairs (bp) organized into four transcription units or open reading frames (ORFs), known as P (polymerase), S (surfaces), C (core), and X (protein X). 4 , 5…”

Section: Introductionmentioning

confidence: 99%

“…The viral characteristics of HBV (genotypes, viral load, specific mutations) and coinfection with HDV are determinants of the course of infection, but are unknown in the region. 3 , 20 , 21 , 22 , 23 …”

Section: Introductionmentioning

confidence: 99%